Cephalon Actiq Extensions Start In 2005, Provigil Isomer On Market In 2006
Cephalon's life-cycle management strategy for the breakthrough cancer pain lozengeActiq includes a sugar-free and fast-acting dosage form
You may also be interested in...
Cephalon plans to meet with FDA to discuss clinical requirements for a Provigil attention deficit hyperactivity disorder indication following positive results from a Phase II pediatric study, CEO Frank Baldino, PhD, said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials